P2Y12-话题@MedSci - 梅斯（MedSci）

#P2Y12#

28篇内容 | 1563人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1940229, encodeId=107a19402293e, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, objectType=article, longId=301028, objectId=7a613010288a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a613010288a, replyNumber=0, likeNumber=76, createdTime=2023-02-01, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a613010288a, moduleTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7a613010288a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940228, encodeId=806f1940228f7, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, objectType=article, longId=294328, objectId=43cc29432875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cc29432875, replyNumber=0, likeNumber=92, createdTime=2023-01-04, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cc29432875, moduleTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43cc29432875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940226, encodeId=d19019402263a, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, objectType=article, longId=212913, objectId=5ce1212913f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce1212913f0, replyNumber=0, likeNumber=83, createdTime=2021-07-16, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce1212913f0, moduleTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ce1212913f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940227, encodeId=1d28194022ea5, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, objectType=article, longId=214509, objectId=d98d214509a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98d214509a2, replyNumber=0, likeNumber=80, createdTime=2022-03-12, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98d214509a2, moduleTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d98d214509a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940222, encodeId=919c1940222ef, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, objectType=article, longId=193805, objectId=2d31193805d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d31193805d5, replyNumber=0, likeNumber=82, createdTime=2020-05-26, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d31193805d5, moduleTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d31193805d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940224, encodeId=bce61940224d4, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, objectType=article, longId=197924, objectId=487a19e924cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=487a19e924cf, replyNumber=0, likeNumber=84, createdTime=2021-06-05, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=487a19e924cf, moduleTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=487a19e924cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940225, encodeId=fbe6194022547, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, objectType=article, longId=198976, objectId=9d641989e681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d641989e681, replyNumber=0, likeNumber=58, createdTime=2021-02-12, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d641989e681, moduleTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9d641989e681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940221, encodeId=a70a1940221f6, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, objectType=article, longId=187599, objectId=d44518e599f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44518e599f3, replyNumber=0, likeNumber=64, createdTime=2020-06-01, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44518e599f3, moduleTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d44518e599f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940223, encodeId=c9cc1940223f0, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, objectType=article, longId=196863, objectId=d648196863d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d648196863d0, replyNumber=0, likeNumber=89, createdTime=2021-06-04, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d648196863d0, moduleTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d648196863d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940219, encodeId=e51d1940219a1, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, objectType=article, longId=183283, objectId=416a18328369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=416a18328369, replyNumber=0, likeNumber=82, createdTime=2020-07-29, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=416a18328369, moduleTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=416a18328369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940220, encodeId=d873194022022, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, objectType=article, longId=187475, objectId=0c5518e475ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5518e475ae, replyNumber=0, likeNumber=70, createdTime=2020-06-09, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5518e475ae, moduleTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0c5518e475ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940216, encodeId=88311940216af, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=JAHA：P2Y12受体抑制剂之辩，东亚与欧美的全新博弈, objectType=article, longId=176089, objectId=c46b1e608984, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c46b1e608984, replyNumber=0, likeNumber=93, createdTime=2020-03-13, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c46b1e608984, moduleTitle=JAHA：P2Y12受体抑制剂之辩，东亚与欧美的全新博弈, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c46b1e608984)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940215, encodeId=2cd91940215a3, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, objectType=article, longId=173295, objectId=7d9e1e32952a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9e1e32952a, replyNumber=0, likeNumber=116, createdTime=2020-03-12, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9e1e32952a, moduleTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7d9e1e32952a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940217, encodeId=9804194021e36, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, objectType=article, longId=178970, objectId=02321e8970bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02321e8970bd, replyNumber=0, likeNumber=113, createdTime=2019-09-08, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02321e8970bd, moduleTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=02321e8970bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940218, encodeId=eec5194021814, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=NEJM：口服P2Y12抑制剂基因指导原则, objectType=article, longId=181908, objectId=d6d81819084b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6d81819084b, replyNumber=0, likeNumber=64, createdTime=2019-12-15, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6d81819084b, moduleTitle=NEJM：口服P2Y12抑制剂基因指导原则, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d6d81819084b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940213, encodeId=7fb11940213fa, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=ESC2018丨氯吡格雷是ACS患者中合并需口服抗凝药人群的更佳P2Y12i选择用药, objectType=article, longId=147547, objectId=6a2e14e54788, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a2e14e54788, replyNumber=0, likeNumber=78, createdTime=2018-11-18, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a2e14e54788, moduleTitle=ESC2018丨氯吡格雷是ACS患者中合并需口服抗凝药人群的更佳P2Y12i选择用药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6a2e14e54788)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940214, encodeId=a6ca1940214b1, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Circulation：ACS合并CKD：P2Y12-ADP受体阻滞剂疗效如何？, objectType=article, longId=153171, objectId=ed171531e1f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed171531e1f1, replyNumber=0, likeNumber=114, createdTime=2018-11-25, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed171531e1f1, moduleTitle=Circulation：ACS合并CKD：P2Y12-ADP受体阻滞剂疗效如何？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ed171531e1f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940212, encodeId=9e46194021289, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=【尖锋档案】P2Y12抑制剂的转换, objectType=article, longId=133590, objectId=c8001335902c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8001335902c, replyNumber=0, likeNumber=77, createdTime=2018-05-21, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8001335902c, moduleTitle=【尖锋档案】P2Y12抑制剂的转换, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c8001335902c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940210, encodeId=d89f1940210ba, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=剧情神反转，P2Y12受体抑制剂怎么转换患者获益更佳？, objectType=article, longId=125134, objectId=94f612513471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94f612513471, replyNumber=0, likeNumber=77, createdTime=2018-07-05, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94f612513471, moduleTitle=剧情神反转，P2Y12受体抑制剂怎么转换患者获益更佳？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94f612513471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940211, encodeId=2d3c194021161, content=<a href='/topic/show?id=18f81361276' target=_blank style='color:#2F92EE;'>#P2Y12#</a>, objectTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, objectType=article, longId=127320, objectId=074b12e320a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b12e320a9, replyNumber=0, likeNumber=65, createdTime=2018-06-18, rootId=0, userName=yeye5224612, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b12e320a9, moduleTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=074b12e320a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

P2Y12

2020-05-29

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！

2023-02-01

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益

2023-01-04

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大

2021-07-16

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析

2022-03-12

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防

2020-05-26

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比

2021-06-05

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效

2021-02-12

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？

2020-06-01

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？

2021-06-04

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险

2020-07-29

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系

2020-06-09

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

JAHA：P2Y12受体抑制剂之辩，东亚与欧美的全新博弈

2020-03-13

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究

2020-03-12

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略

2019-09-08

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

NEJM：口服P2Y12抑制剂基因指导原则

2019-12-15

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

ESC2018丨氯吡格雷是ACS患者中合并需口服抗凝药人群的更佳P2Y12i选择用药

2018-11-18

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Circulation：ACS合并CKD：P2Y12-ADP受体阻滞剂疗效如何？

2018-11-25

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

【尖锋档案】P2Y12抑制剂的转换

2018-05-21

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

剧情神反转，P2Y12受体抑制剂怎么转换患者获益更佳？

2018-07-05

yeye5224612 (审核中...)

前往app查看评论内容

#P2Y12#

Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题

2018-06-18

科室
- - 订阅+
  - 更多科室
工具
服务